Breast cancer stage I

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
5 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 3
Mechanism of action (INN-stem analysis)
Platinum compound 2 substances
Checkpoint inhibitor (PD-1) 1 substance
Antibody-drug conjugate (ADC) 1 substance
Antimetabolite 1 substance
Phase III: 1 Phase II: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • GBG Forschungs GmbH Academic
    CAPECITABINE; CARBOPLATIN; CISPLATIN; SACITUZUMAB GOVITECAN
    2023-510390-33-00 6 countries 2020 n=1,386
    Ended

Phase II

2 trials
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
    2023-508787-29-00 1 country 2024 n=348
    Recruiting
  • Unicancer Academic
    PEMBROLIZUMAB
    2023-504620-26-00 2 countries 2024 n=364
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
WSG Westdeutsche Studiengruppe GmbH Commercial 1 Phase II 1
Unicancer Academic 1 Phase II 1
GBG Forschungs GmbH Academic 1 Phase III 0
New trials by year
2020
1
2024
2
← All indication landscapes